Large-scale testing (Phase 3)Not Yet RecruitingNCT07321860
What this trial is testing
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
Who this might be right for
ALS (Amyotrophic Lateral Sclerosis)
Gipfel Life Sciences GmbH 60